| 1 | Flow cytometric analysis of the murine placenta to evaluate nanoparticle platforms during pregnancy | 1.1 | 1 | Citations (PDF) |
| 2 | Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia | 40.1 | 3 | Citations (PDF) |
| 3 | Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain | 8.8 | 1 | Citations (PDF) |
| 4 | Multiarm-Assisted Design of Dendron-like Degradable Ionizable Lipids Facilitates Systemic mRNA Delivery to the Spleen | 15.7 | 0 | Citations (PDF) |
| 5 | Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complex for hepatic gene editing and T cell engineering | 14.1 | 1 | Citations (PDF) |
| 6 | Rational Design of Nanomedicine for Placental Disorders: Birthing a New Era in Women's Reproductive Health | 11.6 | 11 | Citations (PDF) |
| 7 | Orthogonal Design of Experiments for Engineering of Lipid Nanoparticles for mRNA Delivery to the Placenta | 11.6 | 14 | Citations (PDF) |
| 8 | In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism | 11.6 | 41 | Citations (PDF) |
| 9 | An oncolytic circular RNA therapy | 13.9 | 2 | Citations (PDF) |
| 10 | Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models | 14.1 | 16 | Citations (PDF) |
| 11 | Predictive High-Throughput Platform for Dual Screening of mRNA Lipid Nanoparticle Blood–Brain Barrier Transfection and Crossing | 8.8 | 16 | Citations (PDF) |
| 12 | TGF-βR2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissue | 13.1 | 16 | Citations (PDF) |
| 13 | Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery | 7.7 | 6 | Citations (PDF) |
| 14 | Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager | 18.8 | 7 | Citations (PDF) |
| 15 | In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors | 14.1 | 12 | Citations (PDF) |
| 16 | An immunosuppressive vascular niche drives macrophage polarization and immunotherapy resistance in glioblastoma | 11.3 | 6 | Citations (PDF) |
| 17 | Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy | 24.7 | 15 | Citations (PDF) |
| 18 | High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models | 14.1 | 25 | Citations (PDF) |
| 19 | Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering | 17.1 | 5 | Citations (PDF) |
| 20 | Influence of ionizable lipid tail length on lipid nanoparticle delivery of <scp>mRNA</scp> of varying length | 4.3 | 9 | Citations (PDF) |
| 21 | Vascular endothelial-derived SPARCL1 exacerbates viral pneumonia through pro-inflammatory macrophage activation | 14.1 | 7 | Citations (PDF) |
| 22 | Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions | 15.4 | 14 | Citations (PDF) |
| 23 | High-Throughput <i>In Vivo</i> Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route | 15.4 | 6 | Citations (PDF) |
| 24 | Enhancing in situ cancer vaccines using delivery technologies | 39.3 | 15 | Citations (PDF) |
| 25 | Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo | 13.9 | 10 | Citations (PDF) |
| 26 | Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins | 14.1 | 7 | Citations (PDF) |
| 27 | Optimized microfluidic formulation and organic excipients for improved lipid nanoparticle mediated genome editing | 5.6 | 1 | Citations (PDF) |
| 28 | In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells | 7.7 | 5 | Citations (PDF) |
| 29 | Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery | 20.9 | 3 | Citations (PDF) |
| 30 | Fine-tuning extracellular fluid viscosity enhances gene delivery | 0.0 | 0 | Citations (PDF) |
| 31 | Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery | 23.9 | 4 | Citations (PDF) |
| 32 | Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution | 18.8 | 1 | Citations (PDF) |
| 33 | Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy | 12.9 | 33 | Citations (PDF) |
| 34 | Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis | 14.1 | 77 | Citations (PDF) |
| 35 | Nanoparticle protein corona: from structure and function to therapeutic targeting | 5.6 | 90 | Citations (PDF) |
| 36 | Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents | 12.8 | 10 | Citations (PDF) |
| 37 | Ionizable Lipid Nanoparticles for <i>In Vivo</i> mRNA Delivery to the Placenta during Pregnancy | 15.7 | 76 | Citations (PDF) |
| 38 | Delivery technologies for women’s health applications | 14.8 | 26 | Citations (PDF) |
| 39 | A hydrogel-entrapped live virus immunization | 18.8 | 2 | Citations (PDF) |
| 40 | Exosome-disrupting peptides for cancer immunotherapy | 20.9 | 2 | Citations (PDF) |
| 41 | Rerouting nanoparticles to bone marrow via neutrophil hitchhiking | 23.9 | 4 | Citations (PDF) |
| 42 | Biotechnology: Overcoming biological barriers to nucleic acid delivery using lipid nanoparticles | 5.2 | 26 | Citations (PDF) |
| 43 | In vivo bone marrow microenvironment siRNA delivery using lipid–polymer nanoparticles for multiple myeloma therapy | 7.7 | 23 | Citations (PDF) |
| 44 | Lipid Nanoparticle Delivery of Small Proteins for Potent <i>In Vivo</i> RAS Inhibition | 8.1 | 18 | Citations (PDF) |
| 45 | Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines | 23.9 | 78 | Citations (PDF) |
| 46 | Targeted Nanocarriers Co-Opting Pulmonary Intravascular Leukocytes for Drug Delivery to the Injured Brain | 15.4 | 16 | Citations (PDF) |
| 47 | Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease | 15.4 | 31 | Citations (PDF) |
| 48 | Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines | 7.7 | 31 | Citations (PDF) |
| 49 | In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity | 20.9 | 30 | Citations (PDF) |
| 50 | siRNA Lipid–Polymer Nanoparticles Targeting E-Selectin and Cyclophilin A in Bone Marrow for Combination Multiple Myeloma Therapy | 1.9 | 5 | Citations (PDF) |
| 51 | Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering | 8.9 | 35 | Citations (PDF) |
| 52 | mRNA Lipid Nanoparticles for <i>Ex Vivo</i> Engineering of Immunosuppressive T Cells for Autoimmunity Therapies | 8.8 | 12 | Citations (PDF) |
| 53 | Responsive biomaterials: optimizing control of cancer immunotherapy | 32.0 | 36 | Citations (PDF) |
| 54 | Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells | 8.8 | 99 | Citations (PDF) |
| 55 | Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery | 11.3 | 42 | Citations (PDF) |
| 56 | Rational design of anti‐inflammatory lipid nanoparticles for mRNA delivery | 4.3 | 35 | Citations (PDF) |
| 57 | Lighting the way to personalized mRNA immune cell therapies | 11.3 | 3 | Citations (PDF) |
| 58 | Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc | 4.4 | 10 | Citations (PDF) |
| 59 | Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE) | 11.3 | 73 | Citations (PDF) |
| 60 | Endothelial plasticity drives aberrant vascularization and impedes cardiac repair after myocardial infarction | 4.0 | 12 | Citations (PDF) |
| 61 | Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells | 11.3 | 68 | Citations (PDF) |
| 62 | Lipid nanodiscs give cancer a STING | 20.9 | 2 | Citations (PDF) |
| 63 | Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment | 15.7 | 93 | Citations (PDF) |
| 64 | Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes | 5.4 | 31 | Citations (PDF) |
| 65 | Nanotechnology-based strategies against SARS-CoV-2 variants | 23.9 | 91 | Citations (PDF) |
| 66 | RGD peptide-based lipids for targeted mRNA delivery and gene editing applications | 4.5 | 26 | Citations (PDF) |
| 67 | A (Controlled) Spill of IL-2 for Localized Treatment of Mesothelioma | 6.4 | 0 | Citations (PDF) |
| 68 | Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research | 5.1 | 22 | Citations (PDF) |
| 69 | Delivery technologies for in utero gene therapy | 15.7 | 41 | Citations (PDF) |
| 70 | A Nanoparticle Platform for Accelerated In Vivo Oral Delivery Screening of Nucleic Acids | 2.3 | 19 | Citations (PDF) |
| 71 | Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver | 5.8 | 138 | Citations (PDF) |
| 72 | Ionizable lipid nanoparticles for in utero mRNA delivery | 11.3 | 141 | Citations (PDF) |
| 73 | Nanomaterials for T-cell cancer immunotherapy | 23.9 | 231 | Citations (PDF) |
| 74 | Peptide functionalized liposomes for receptor targeted cancer therapy | 4.1 | 35 | Citations (PDF) |
| 75 | Delivery technologies to engineer natural killer cells for cancer immunotherapy | 4.1 | 29 | Citations (PDF) |
| 76 | Delivery technologies for T cell gene editing: Applications in cancer immunotherapy | 10.0 | 60 | Citations (PDF) |
| 77 | Lipid Nanoparticle-Mediated Delivery of mRNA Therapeutics and Vaccines | 10.0 | 73 | Citations (PDF) |
| 78 | Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device | 8.8 | 169 | Citations (PDF) |
| 79 | Microfluidic formulation of nanoparticles for biomedical applications | 12.3 | 220 | Citations (PDF) |
| 80 | One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA | 15.7 | 94 | Citations (PDF) |
| 81 | An ionizable lipid toolbox for RNA delivery | 14.1 | 311 | Citations (PDF) |
| 82 | Chiral Supraparticles for Controllable Nanomedicine | 24.7 | 137 | Citations (PDF) |
| 83 | Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy | 15.7 | 41 | Citations (PDF) |
| 84 | Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche | 18.8 | 94 | Citations (PDF) |
| 85 | Nanomaterials for Therapeutic RNA Delivery | 13.9 | 88 | Citations (PDF) |
| 86 | Proton-driven transformable nanovaccine for cancer immunotherapy | 23.9 | 237 | Citations (PDF) |
| 87 | Cyclodextrins in drug delivery: applications in gene and combination therapy | 4.7 | 76 | Citations (PDF) |
| 88 | Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering | 8.8 | 400 | Citations (PDF) |
| 89 | Engineering precision nanoparticles for drug delivery | 39.3 | 4,578 | Citations (PDF) |
| 90 | Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening | 11.3 | 135 | Citations (PDF) |
| 91 | Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy | 8.5 | 101 | Citations (PDF) |
| 92 | Delivery technologies for cancer immunotherapy | 39.3 | 1,889 | Citations (PDF) |
| 93 | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy | 15.4 | 122 | Citations (PDF) |
| 94 | Nanomaterial Interactions with Human Neutrophils | 5.5 | 54 | Citations (PDF) |
| 95 | Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes | 11.3 | 36 | Citations (PDF) |
| 96 | Biomaterials for vaccine-based cancer immunotherapy | 11.3 | 144 | Citations (PDF) |
| 97 | Advances in Biomaterials for Drug Delivery | 24.7 | 665 | Citations (PDF) |
| 98 | Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis | 14.1 | 28 | Citations (PDF) |
| 99 | Engineering and physical sciences in oncology: challenges and opportunities | 24.2 | 214 | Citations (PDF) |
| 100 | Nanostructured Fibrous Membranes with Rose Spike-Like Architecture | 8.8 | 73 | Citations (PDF) |
| 101 | Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy | 8.8 | 553 | Citations (PDF) |
| 102 | TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer | 11.3 | 64 | Citations (PDF) |
| 103 | Cooperative Effects of Matrix Stiffness and Fluid Shear Stress on Endothelial Cell Behavior | 0.4 | 120 | Citations (PDF) |
| 104 | Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies | 4.3 | 27 | Citations (PDF) |
| 105 | Surfactant functionalization induces robust, differential adhesion of tumor cells and blood cells to charged nanotube-coated biomaterials under flow | 12.3 | 44 | Citations (PDF) |
| 106 | Leukocytes as carriers for targeted cancer drug delivery | 5.2 | 63 | Citations (PDF) |
| 107 | Unnatural killer cells: TRAIL-coated leukocytes that kill cancer cells in the circulation 2014, , 1-2 | | 1 | Citations (PDF) |
| 108 | Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering | 2.6 | 8 | Citations (PDF) |
| 109 | Physical Biology in Cancer. 3. The role of cell glycocalyx in vascular transport of circulating tumor cells | 4.4 | 66 | Citations (PDF) |
| 110 | Differentially charged nanomaterials control selectin-mediated adhesion and isolation of cancer cells and leukocytes under flow 2014, , 1-2 | | 1 | Citations (PDF) |
| 111 | A microfluidic device to select for cells based on chemotactic phenotype | 0.3 | 8 | Citations (PDF) |
| 112 | TRAIL-coated leukocytes that kill cancer cells in the circulation | 7.7 | 183 | Citations (PDF) |
| 113 | Fluid Shear Stress Increases Neutrophil Activation via Platelet-Activating Factor | 0.4 | 57 | Citations (PDF) |
| 114 | Correction | 0.4 | 0 | Citations (PDF) |
| 115 | Computational and Experimental Models of Cancer Cell Response to Fluid Shear Stress | 2.7 | 164 | Citations (PDF) |
| 116 | Stem Cell Enrichment with Selectin Receptors: Mimicking the pH Environment of Trauma | 4.0 | 14 | Citations (PDF) |
| 117 | Fluid shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors | 2.8 | 149 | Citations (PDF) |
| 118 | Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling Leukocytes | 3.4 | 29 | Citations (PDF) |
| 119 | Shear-Induced Resistance to Neutrophil Activation via the Formyl Peptide Receptor | 0.4 | 29 | Citations (PDF) |
| 120 | E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells | 11.3 | 72 | Citations (PDF) |
